文献速递白血病MDS 与骨髓增殖性肿瘤

在可移植的慢性粒单核细胞白血病患者来源异种移植模型中通过体内筛选鉴定有效药物治疗

Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
PubMed 文献 · Leukemia · 2020-06-24

研究通过慢病毒表达MN1补充致癌基因并移植转导的原代CMML单核细胞至免疫缺陷小鼠,建立三个可连续移植的CMML-PDX模型,其保留疾病相关基因突变并在体内重现疾病。MN1补充的CMML细胞可连续移植至第5代,支持针对NRAS等突变的体内RNA干扰筛选;阿扎胞苷与MEK抑制剂曲美替尼联合additively抑制ERK磷酸化并清除突变NRAS信号,联合治疗较单药显著延长CMML小鼠生存。作者提出该联合方案用于NRAS突变CMML并建议临床开发。

要点

  • MN1补充使原代CMML细胞获得连续移植能力至第5代。
  • 阿扎胞苷联合曲美替尼additively抑制ERK磷酸化并清除突变NRAS信号。
  • 联合治疗较单药显著延长CMML小鼠生存,作者建议临床开发。

核心结论

  • 作者鉴定阿扎胞苷与曲美替尼联合为NRAS突变CMML的有效治疗并提出其临床开发。

研究设计与样本

  • 研究使用慢病毒表达MN1进行致癌补充,将转导的原代CMML单核细胞移植入免疫缺陷小鼠。
  • 建立三个可连续移植的CMML-PDX模型,具有疾病相关基因突变并在体内重现疾病。

主要发现

  • 异位MN1表达增强CMML细胞增殖,否则这些细胞在二次移植时不能植入。
  • MN1补充的CMML细胞可连续移植至受体小鼠最多5代。
  • 稳健植入支持针对CMML相关突变基因包括NRAS的体内RNA干扰筛选,确认其在MN1存在时功能相关性保留。
  • 阿扎胞苷与MEK抑制剂曲美替尼联合additively抑制ERK磷酸化并清除突变NRAS信号。
  • 联合治疗较单药治疗显著延长CMML小鼠生存。

关键数值与推荐

  • MN1补充的CMML细胞可连续移植至受体小鼠最多5代。
  • 联合治疗较单药治疗显著延长CMML小鼠生存,原文未报告具体生存数值。

临床怎么用

  • 作者提出阿扎胞苷与曲美替尼联合用于NRAS突变CMML并建议其临床开发。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To establish novel and effective treatment combinations for chronic myelomonocytic leukemia (CMML) preclinically, we hypothesized that supplementation of CMML cells with the human oncogene Meningioma 1 (MN1) promotes expansion and serial transplantability in mice, while maintaining the functional dependencies of these cells on their original genetic profile. Using lentiviral expression of MN1 for oncogenic supplementation and transplanting transduced primary mononuclear CMML cells into immunocompromised mice, we established three serially transplantable CMML-PDX models with disease-related gene mutations that recapitulate the disease in vivo. Ectopic MN1 expression was confirmed to enhance the proliferation of CMML cells, which otherwise did not engraft upon secondary transplantation. Furthermore, MN1-supplemented CMML cells were serially transplantable into recipient mice up to 5 generations. This robust engraftment enabled an in vivo RNA interference screening targeting CMML-related mutated genes including NRAS, confirming that their functional relevance is preserved in the presence of MN1. The novel combination treatment with azacitidine and the MEK-inhibitor trametinib additively inhibited ERK-phosphorylation and thus depleted the signal from mutated NRAS. The combination treatment significantly prolonged survival of CMML mice compared to single-agent treatment. Thus, we identified the combination of azacitidine and trametinib as an effective treatment in NRAS-mutated CMML and propose its clinical development.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kloos A, Mintzas K, Winckler L, et al. Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia. 2020. PMID: 32576961. doi:10.1038/s41375-020-0929-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。